177 related articles for article (PubMed ID: 22605555)
1. Genotoxicity of poly(propylene imine) dendrimers.
Ziemba B; Matuszko G; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biopolymers; 2012 Aug; 97(8):642-8. PubMed ID: 22605555
[TBL] [Abstract][Full Text] [Related]
2. In vivo toxicity of poly(propyleneimine) dendrimers.
Ziemba B; Janaszewska A; Ciepluch K; Krotewicz M; Fogel WA; Appelhans D; Voit B; Bryszewska M; Klajnert B
J Biomed Mater Res A; 2011 Nov; 99(2):261-8. PubMed ID: 21976451
[TBL] [Abstract][Full Text] [Related]
3. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M
Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871
[TBL] [Abstract][Full Text] [Related]
4. Influence of fourth generation poly(propyleneimine) dendrimers on blood cells.
Ziemba B; Halets I; Shcharbin D; Appelhans D; Voit B; Pieszynski I; Bryszewska M; Klajnert B
J Biomed Mater Res A; 2012 Nov; 100(11):2870-80. PubMed ID: 22623362
[TBL] [Abstract][Full Text] [Related]
5. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity.
Drzewińska J; Appelhans D; Voit B; Bryszewska M; Klajnert B
Biochem Biophys Res Commun; 2012 Oct; 427(1):197-201. PubMed ID: 22995301
[TBL] [Abstract][Full Text] [Related]
6. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers.
Agashe HB; Babbar AK; Jain S; Sharma RK; Mishra AK; Asthana A; Garg M; Dutta T; Jain NK
Nanomedicine; 2007 Jun; 3(2):120-7. PubMed ID: 17572354
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer.
Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B
Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266
[TBL] [Abstract][Full Text] [Related]
8. Interaction study between maltose-modified PPI dendrimers and lipidic model membranes.
Wrobel D; Appelhans D; Signorelli M; Wiesner B; Fessas D; Scheler U; Voit B; Maly J
Biochim Biophys Acta; 2015 Jul; 1848(7):1490-501. PubMed ID: 25843678
[TBL] [Abstract][Full Text] [Related]
9. The influence of maltose modified poly(propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability.
Ciolkowski M; Pałecz B; Appelhans D; Voit B; Klajnert B; Bryszewska M
Colloids Surf B Biointerfaces; 2012 Jun; 95():103-8. PubMed ID: 22410344
[TBL] [Abstract][Full Text] [Related]
10. Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
Klementieva O; Benseny-Cases N; Gella A; Appelhans D; Voit B; Cladera J
Biomacromolecules; 2011 Nov; 12(11):3903-9. PubMed ID: 21936579
[TBL] [Abstract][Full Text] [Related]
11. Effect of poly(propylene imine) glycodendrimers on β-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer's disease.
Klementieva O; Aso E; Filippini D; Benseny-Cases N; Carmona M; Juvés S; Appelhans D; Cladera J; Ferrer I
Biomacromolecules; 2013 Oct; 14(10):3570-80. PubMed ID: 24004423
[TBL] [Abstract][Full Text] [Related]
12. Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5'-triphosphates.
Szulc A; Signorelli M; Schiraldi A; Appelhans D; Voit B; Bryszewska M; Klajnert-Maculewicz B; Fessas D
Int J Pharm; 2015 Nov; 495(2):940-7. PubMed ID: 26456295
[TBL] [Abstract][Full Text] [Related]
13. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
14. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Dec; 65(12):891-5. PubMed ID: 21284258
[TBL] [Abstract][Full Text] [Related]
15. Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles.
Khalid H; Mukherjee SP; O'Neill L; Byrne HJ
J Appl Toxicol; 2016 Mar; 36(3):464-73. PubMed ID: 26671548
[TBL] [Abstract][Full Text] [Related]
16. Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities.
Zhao C; Wang Y; Su Y; Zhang H; Ding L; Yan X; Zhao D; Shao N; Ye X; Cheng Y
Int J Pharm; 2011 Dec; 421(2):301-9. PubMed ID: 22001794
[TBL] [Abstract][Full Text] [Related]
17. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation.
Wang F; Cai X; Su Y; Hu J; Wu Q; Zhang H; Xiao J; Cheng Y
Acta Biomater; 2012 Dec; 8(12):4304-13. PubMed ID: 22842039
[TBL] [Abstract][Full Text] [Related]
18. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer.
Agashe HB; Dutta T; Garg M; Jain NK
J Pharm Pharmacol; 2006 Nov; 58(11):1491-8. PubMed ID: 17132212
[TBL] [Abstract][Full Text] [Related]
19. Internalization and intracellular trafficking of poly(propylene imine) glycodendrimers with maltose shell in melanoma cells.
Filimon A; Sima LE; Appelhans D; Voit B; Negroiu G
Curr Med Chem; 2012; 19(29):4955-68. PubMed ID: 23033945
[TBL] [Abstract][Full Text] [Related]
20. Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers.
Kuo JH; Jan MS; Lin YL
J Control Release; 2007 Jul; 120(1-2):51-9. PubMed ID: 17537537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
